 Mark Greyson
Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carpal Tunnel Syndrome | 2 | 2025 | 30 | 0.930 |
Why?
| | Decompression, Surgical | 1 | 2025 | 115 | 0.860 |
Why?
| | Nerve Transfer | 1 | 2023 | 11 | 0.820 |
Why?
| | Hand Injuries | 2 | 2020 | 32 | 0.800 |
Why?
| | Upper Extremity | 2 | 2023 | 110 | 0.790 |
Why?
| | Reoperation | 2 | 2025 | 600 | 0.780 |
Why?
| | Endoscopy | 1 | 2025 | 327 | 0.740 |
Why?
| | Contracture | 1 | 2020 | 21 | 0.670 |
Why?
| | Skin Transplantation | 1 | 2020 | 85 | 0.640 |
Why?
| | Cicatrix | 1 | 2020 | 70 | 0.630 |
Why?
| | Muscle, Skeletal | 2 | 2024 | 1772 | 0.500 |
Why?
| | Burns | 1 | 2020 | 357 | 0.470 |
Why?
| | Postoperative Complications | 2 | 2025 | 2862 | 0.400 |
Why?
| | Surgical Flaps | 3 | 2024 | 145 | 0.390 |
Why?
| | Iliac Artery | 2 | 2024 | 57 | 0.260 |
Why?
| | School Admission Criteria | 1 | 2026 | 34 | 0.240 |
Why?
| | Surgery, Plastic | 1 | 2026 | 52 | 0.230 |
Why?
| | Personnel Selection | 1 | 2026 | 88 | 0.220 |
Why?
| | Surgical Wound Infection | 2 | 2025 | 325 | 0.220 |
Why?
| | Myocutaneous Flap | 1 | 2024 | 10 | 0.220 |
Why?
| | Rectus Abdominis | 1 | 2024 | 17 | 0.220 |
Why?
| | Femoral Neoplasms | 1 | 2024 | 10 | 0.210 |
Why?
| | Vascularized Composite Allotransplantation | 1 | 2024 | 31 | 0.210 |
Why?
| | Phantom Limb | 1 | 2023 | 3 | 0.210 |
Why?
| | Fractures, Open | 1 | 2024 | 32 | 0.200 |
Why?
| | Tendon Injuries | 1 | 2024 | 68 | 0.200 |
Why?
| | Perforator Flap | 1 | 2023 | 34 | 0.200 |
Why?
| | Peripheral Nerves | 1 | 2023 | 72 | 0.200 |
Why?
| | Knee Injuries | 1 | 2024 | 103 | 0.200 |
Why?
| | Propensity Score | 1 | 2025 | 343 | 0.200 |
Why?
| | Sarcoma, Ewing | 1 | 2024 | 100 | 0.190 |
Why?
| | Mouth Neoplasms | 1 | 2022 | 89 | 0.180 |
Why?
| | Neoplasms, Second Primary | 1 | 2022 | 98 | 0.180 |
Why?
| | Fracture Fixation, Internal | 1 | 2024 | 202 | 0.180 |
Why?
| | Electromyography | 1 | 2023 | 412 | 0.170 |
Why?
| | Education, Medical, Graduate | 1 | 2026 | 539 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2026 | 16626 | 0.160 |
Why?
| | Esthetics | 1 | 2020 | 47 | 0.160 |
Why?
| | Artificial Limbs | 1 | 2023 | 215 | 0.160 |
Why?
| | Replantation | 1 | 2019 | 31 | 0.150 |
Why?
| | Anesthesia | 1 | 2022 | 250 | 0.150 |
Why?
| | Amputation, Traumatic | 1 | 2019 | 21 | 0.150 |
Why?
| | Trigger Finger Disorder | 1 | 2018 | 7 | 0.140 |
Why?
| | Head and Neck Neoplasms | 1 | 2022 | 558 | 0.130 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2022 | 643 | 0.130 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2980 | 0.130 |
Why?
| | Recovery of Function | 1 | 2020 | 697 | 0.120 |
Why?
| | Internship and Residency | 1 | 2026 | 1244 | 0.110 |
Why?
| | Physical Therapy Modalities | 1 | 2018 | 323 | 0.110 |
Why?
| | Humans | 11 | 2026 | 142526 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2024 | 11298 | 0.100 |
Why?
| | Referral and Consultation | 1 | 2018 | 822 | 0.090 |
Why?
| | Dilatation, Pathologic | 1 | 2011 | 62 | 0.090 |
Why?
| | Molecular Probes | 1 | 2011 | 34 | 0.090 |
Why?
| | Coloring Agents | 1 | 2011 | 96 | 0.080 |
Why?
| | Male | 6 | 2026 | 70910 | 0.080 |
Why?
| | Intercellular Junctions | 1 | 2010 | 38 | 0.080 |
Why?
| | Plasminogen Activator Inhibitor 1 | 1 | 2010 | 89 | 0.080 |
Why?
| | Female | 5 | 2026 | 76624 | 0.080 |
Why?
| | Arteries | 1 | 2011 | 260 | 0.070 |
Why?
| | Cell Communication | 1 | 2010 | 312 | 0.070 |
Why?
| | Aged | 2 | 2025 | 25117 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 260 | 0.070 |
Why?
| | Middle Aged | 3 | 2025 | 35049 | 0.070 |
Why?
| | Adult | 3 | 2026 | 39715 | 0.070 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2010 | 448 | 0.060 |
Why?
| | Postoperative Care | 2 | 2019 | 281 | 0.060 |
Why?
| | Rupture | 1 | 2024 | 88 | 0.050 |
Why?
| | Endothelial Cells | 1 | 2010 | 832 | 0.050 |
Why?
| | Leg Injuries | 1 | 2024 | 25 | 0.050 |
Why?
| | Open Fracture Reduction | 1 | 2024 | 32 | 0.050 |
Why?
| | Femur Head | 1 | 2024 | 41 | 0.050 |
Why?
| | Soft Tissue Injuries | 1 | 2024 | 34 | 0.050 |
Why?
| | Free Tissue Flaps | 1 | 2024 | 52 | 0.050 |
Why?
| | Models, Animal | 1 | 2024 | 392 | 0.050 |
Why?
| | Hand | 1 | 2023 | 165 | 0.050 |
Why?
| | Time-to-Treatment | 1 | 2024 | 227 | 0.050 |
Why?
| | Range of Motion, Articular | 1 | 2024 | 415 | 0.040 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2022 | 116 | 0.040 |
Why?
| | Graft Survival | 1 | 2024 | 518 | 0.040 |
Why?
| | Swine | 1 | 2024 | 832 | 0.040 |
Why?
| | Bone Neoplasms | 1 | 2024 | 249 | 0.040 |
Why?
| | Adolescent | 1 | 2020 | 22326 | 0.040 |
Why?
| | Esophagoscopy | 1 | 2022 | 219 | 0.040 |
Why?
| | Graft Rejection | 1 | 2024 | 550 | 0.040 |
Why?
| | Child | 1 | 2020 | 22562 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2022 | 1404 | 0.040 |
Why?
| | Microsurgery | 1 | 2019 | 78 | 0.040 |
Why?
| | Anastomosis, Surgical | 1 | 2019 | 159 | 0.040 |
Why?
| | Time Factors | 2 | 2024 | 7006 | 0.030 |
Why?
| | Disability Evaluation | 1 | 2018 | 304 | 0.030 |
Why?
| | Triage | 1 | 2019 | 250 | 0.030 |
Why?
| | Preoperative Care | 1 | 2019 | 377 | 0.030 |
Why?
| | Prospective Studies | 1 | 2026 | 7862 | 0.030 |
Why?
| | Comorbidity | 1 | 2018 | 1678 | 0.020 |
Why?
| | Methods | 1 | 2011 | 68 | 0.020 |
Why?
| | Ligation | 1 | 2011 | 93 | 0.020 |
Why?
| | Animals | 3 | 2024 | 37697 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 111 | 0.020 |
Why?
| | Arterioles | 1 | 2010 | 57 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 144 | 0.020 |
Why?
| | Coculture Techniques | 1 | 2010 | 248 | 0.020 |
Why?
| | United States | 1 | 2026 | 15447 | 0.020 |
Why?
| | Protein Transport | 1 | 2010 | 446 | 0.020 |
Why?
| | Calcium Signaling | 1 | 2010 | 248 | 0.020 |
Why?
| | Coronary Vessels | 1 | 2010 | 250 | 0.020 |
Why?
| | Tandem Mass Spectrometry | 1 | 2010 | 566 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2010 | 1364 | 0.020 |
Why?
| | Heart Transplantation | 1 | 2010 | 723 | 0.010 |
Why?
| | Proteomics | 1 | 2010 | 1152 | 0.010 |
Why?
| | Mice | 2 | 2011 | 18172 | 0.010 |
Why?
| | Mice, Knockout | 1 | 2010 | 3081 | 0.010 |
Why?
| | Antibodies, Monoclonal | 1 | 2010 | 1471 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2010 | 4167 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2011 | 4483 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2010 | 5967 | 0.010 |
Why?
|
|
Greyson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|